Charter Medical Ltd., a Fenner PLC subsidiary (LSE:FENR), a globally recognized manufacturer of products for the regenerative medicine and bioprocessing industries, announced today that it has established a strategic partnership with INCELL Corporation, an innovative developer and manufacturer of specialty medias and formulated solutions for tissue and cell collection, transport, processing and storage. The partnership will enable both organizations to meet the growing customer demand for more comprehensive solutions in cell culture, cell expansion, and cryopreservation.

Mary Pat Moyer, Founder, CEO and Chief Science Officer, INCELL Corporation commented, “I envision that synchronizing our companies’ complementary capabilities and sales will help accelerate time to market of quality cell-based and personalized therapies for cancer, regenerative medicine, and many diseases.”

Gael Peron, President, Charter Medical stated, “We are very excited about this opportunity as INCELL’s expertise in specialty medias complements Charter Medical’s expertise in single-use products and helps transform our business into a more complete solution provider for the cell and gene therapy and bioprocessing industries we currently serve today.” Under the terms of this agreement, Charter Medical will hold the exclusive rights to market, sell, and distribute INCELL media products on a global basis.